News Releases

Date Title and Summary Additional Formats
Toggle Summary ChemoCentryx Reports Second Quarter 2017 Financial Results and Recent Highlights
-- Pivotal Phase III ADVOCATE trial of avacopan on track to complete enrollment in mid-2018 as projected -- -- Launching second trial of avacopan in patients with C3 Glomerulopathy (C3G) -- -- Conference call today at 5:00 p.m. Eastern Time -- MOUNTAIN VIEW, Calif. , Aug.
View HTML
Toggle Summary ChemoCentryx to Hold Second Quarter 2017 Financial Results Conference Call on Tuesday, August 8, 2017
MOUNTAIN VIEW, Calif. , July 26, 2017 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq:CCXI), a biopharmaceutical company developing new medications targeted at inflammatory and autoimmune diseases and cancer, today announced that the Company's second quarter 2017 financial results will be released
View HTML
Toggle Summary Oral Presentations at ERA-EDTA Congress Highlight Fourth Potential Indication for Avacopan and Potential for CCR2 Inhibition in Focal Segmental Glomerulosclerosis (FSGS)
-- Clinical Study Shows Drop in Proteinuria in Patients Treated with Avacopan for IgA Nephropathy (IgAN) -- -- Potential of CCR2 Inhibitor as a Therapeutic Treatment Option for FSGS Validated -- MOUNTAIN VIEW, Calif. , June 06, 2017 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc.
View HTML
Toggle Summary ChemoCentryx to Present at Two Upcoming Investor Conferences
MOUNTAIN VIEW, Calif. , May 24, 2017 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq:CCXI), a biopharmaceutical company developing new medications targeted at inflammatory and autoimmune diseases and cancer, announced today that Thomas J. Schall , Ph.D., President and Chief Executive Officer, will
View HTML
Toggle Summary ChemoCentryx Granted EU Orphan Drug Designation for Avacopan in the Treatment of Debilitating Kidney Disease C3 Glomerulopathy (C3G)
MOUNTAIN VIEW, Calif. , May 23, 2017 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq:CCXI), a biopharmaceutical company developing new medications targeted at inflammatory and autoimmune diseases and cancer, announced today that the European Medicines Agency (EMA) has granted orphan medicinal
View HTML
Toggle Summary ChemoCentryx Reports First Quarter 2017 Financial Results
-- Phase III clinical trial of avacopan for the treatment of ANCA Vasculitis underway as Journal of American Society of Nephrology (JASN) publishes results of successful Phase II CLEAR clinical trial -- -- Received FDA Orphan Drug Designation for avacopan in the treatment of C3 Glomerulopathy (C3G)
View HTML
Toggle Summary ChemoCentryx to Hold First Quarter 2017 Financial Results Conference Call on Wednesday, May 10, 2017
MOUNTAIN VIEW, Calif. , April 27, 2017 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq:CCXI), today announced that the Company's first quarter 2017 financial results will be released after market close on Wednesday, May 10, 2017 . ChemoCentryx executive management will host a conference call
View HTML
Toggle Summary ChemoCentryx Receives FDA Orphan Drug Designation for Avacopan in the Treatment of Debilitating Kidney Disease C3 Glomerulopathy (C3G)
MOUNTAIN VIEW, Calif. , March 22, 2017 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq:CCXI), a biopharmaceutical company developing new medications targeted at inflammatory and autoimmune diseases and cancer, announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug
View HTML
Toggle Summary ChemoCentryx Reports Fourth Quarter and Full Year 2016 Financial Results
-- Expanded Vifor Pharma partnership now totals $155 million in upfront cash commitments, $1.2 billion in potential milestone payments, plus substantial royalties on potential net sales -- -- Initiated Phase III clinical trial of Avacopan for the treatment of ANCA Vasculitis -- -- Conference call
View HTML
Toggle Summary ChemoCentryx to Hold Fourth Quarter 2016 Financial Results Conference Call on Tuesday, March 14, 2017
MOUNTAIN VIEW, Calif. , March 01, 2017 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq:CCXI), today announced that the Company's fourth quarter 2016 financial results will be released after market close on Tuesday, March 14, 2017 . ChemoCentryx executive management will host a conference call
View HTML